F T Valentine
Overview
Explore the profile of F T Valentine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
846
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gulick R, Mellors J, Havlir D, Eron J, Meibohm A, Condra J, et al.
Ann Intern Med
. 2000 Jul;
133(1):35-9.
PMID: 10877738
Background: Antiretroviral regimens containing HIV protease inhibitors suppress viremia in HIV-infected patients, but the durability of this effect is not known. Objective: To describe the 3-year follow-up of patients randomly...
2.
Gulick R, McAULIFFE V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein D, et al.
Ann Intern Med
. 1999 Mar;
130(6):510-4.
PMID: 10075619
Background: Hypericin, the active compound in St. John's Wort, has antiretroviral activity in vitro. Many HIV-infected persons use St. John's wort. Objective: To evaluate the safety and antiretroviral activity of...
3.
Valentine F, Paolino A, Saito A, Holzman R
AIDS Res Hum Retroviruses
. 1998 Jul;
14 Suppl 2:S161-6.
PMID: 9672234
Lymphocyte-proliferative responses (LPRs) to HIV antigens are absent or of low magnitude in the majority of HIV-infected individuals, even early in the disease. However, lymphocytes from 2% to 3% of...
4.
Gulick R, Mellors J, Havlir D, Eron J, Gonzalez C, McMahon D, et al.
N Engl J Med
. 1997 Sep;
337(11):734-9.
PMID: 9287228
Background: The new protease inhibitors are potent inhibitors of the human immunodeficiency virus (HIV), and in combination with other antiretroviral drugs they may be able to cause profound and sustained...
5.
Kundu S, Katzenstein D, Valentine F, Spino C, Efron B, Merigan T
J Acquir Immune Defic Syndr Hum Retrovirol
. 1997 Aug;
15(4):269-74.
PMID: 9292585
Therapeutic vaccination has been proposed as a strategy to augment immune mechanisms to control viral replication and slow clinical progression of HIV infection to disease. Following recombinant gp160 (r-gp160) immunization...
6.
Valentine F, Kundu S, Haslett P, Katzenstein D, Beckett L, Spino C, et al.
J Infect Dis
. 1996 Jun;
173(6):1336-46.
PMID: 8648205
Immune responses provoked by human immunodeficiency virus (HIV) infection ultimately are insufficient to control the disease and do not include strong lymphocyte-proliferative responses to HIV antigens or antibodies to many...
7.
Nardelli B, Gonzalez C, Schechter M, Valentine F
Proc Natl Acad Sci U S A
. 1995 Aug;
92(16):7312-6.
PMID: 7638187
We have investigated the ability of human immunodeficiency virus (HIV)-infected cells to kill uninfected CD4+ lymphocytes. Infected peripheral blood mononuclear cells were cocultured with autologous 51Cr-labeled uninfected cells. Rapid death...
8.
Grasela T, Walawander C, Beltangady M, Knupp C, Martin R, Dunkle L, et al.
J Infect Dis
. 1994 Jun;
169(6):1250-5.
PMID: 8195601
Phase I dose-escalating trials of didanosine revealed dose-limiting toxicities, including pancreatitis, and established a total daily dose of 12.5 mg/kg/day as the maximum tolerated dose. Clinical and pharmacokinetic data of...
9.
Kelker H, Schlesinger D, Valentine F
J Immunol
. 1994 Apr;
152(8):4139-48.
PMID: 8144976
An HIV-1 envelope protein gp120-derived monomeric peptide (amino acid residues 419-439) and its homologous multiple chain peptide (MCP) construct were compared for immunogenicity in mice. The Abs stimulated by the...
10.
Hughes M, Stein D, Gundacker H, Valentine F, Phair J, Volberding P
J Infect Dis
. 1994 Jan;
169(1):28-36.
PMID: 7903975
Changes in CD4 lymphocyte counts are widely used in monitoring human immunodeficiency virus (HIV)-infected patients for disease progression. However, random fluctuations may obscure clinically significant changes. CD4 cell counts from...